Michelle Dees
Psychiatry · Chicago, ILNPI 1871648642
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $237,466 of the $288,525 with a category attached, or 82.3%. It is spread thinly across 24 manufacturers, the largest accounting for just 23.0%. Reporting peaked in 2019 at $73,149 and has fallen 99.2% since, to $599 in 2025. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 644 payments — averaging $448.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$66K
- Avanir Pharmaceuticals, Inc.$65K
- Otsuka America Pharmaceutical, Inc.$51K
- Teva Pharmaceuticals USA, Inc.$46K
- AbbVie$27K
- Alkermes, Inc.$19K
- plus $14K from 18 others
What the payments were for
- Consulting fees$3,0001%
- Speaking & faculty fees$237,46682%
- Travel & lodging$34,14812%
- Food & beverage$13,7045%
- Education$2070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 81 | $66,314 |
| Avanir Pharmaceuticals, Inc. | 99 | $65,497 |
| Otsuka America Pharmaceutical, Inc. | 109 | $51,024 |
| Teva Pharmaceuticals USA, Inc. | 44 | $46,394 |
| AbbVie(2 entities) | 158 | $26,847 |
| Alkermes, Inc. | 32 | $18,714 |
| Sunovion Pharmaceuticals Inc. | 34 | $10,343 |
| Johnson & Johnson | 31 | $1,093 |
| Neuronetics, Inc. | 15 | $893 |
| Neurocrine Biosciences, Inc. | 7 | $453 |
| Axsome Therapeutics, Inc. | 10 | $307 |
| Bioxcel Therapeutics, Inc. | 2 | $136 |
| Brainsway USA Inc | 1 | $111 |
| Tris Pharma Inc | 5 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Lundbeck LLC | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Galderma Laboratories, L.p. | 2 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Merck | 1 | $20 |
| Almatica Pharma LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUEDEXTA$104,476
- ARISTADA$73,144
- CAPLYTA$65,629
- AUSTEDO$45,763
- VRAYLAR$24,433
- ARISTADA INITIO$18,286
- LATUDA$9,755
- ABILIFY MAINTENA$8,228
- NEUROSTAR TMS THERAPY$475
- SPRAVATO$460
- INGREZZA$362
- REXULTI$122
- Brainsway Deep TMS$111
How this compares
$288,525 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 23 | $272,697 |
| Hydroxyzine Hcl | 111 | $2,388 |
| Lurasidone Hcl | 14 | $871 |
| Olanzapine | 83 | $660 |
| Quetiapine Fumarate | 69 | $491 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $437 |
| Aripiprazole | 49 | $383 |
| Mirtazapine | 49 | $333 |
| Buspirone Hcl | 44 | $265 |
| Alprazolam | 35 | $244 |
| Atorvastatin Calcium | 51 | $212 |
| Pantoprazole Sodium | 47 | $200 |
| Propranolol Hcl | 14 | $197 |
| Haloperidol | 23 | $154 |
| Clonazepam | 15 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $46,394 | $272,69723 claims |
| Lilly USA, LLCOlanzapine | $18 | $66083 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Chicago
- Mitchell GlaserChicago$752K
- Peter WeidenChicago$440K
- Jeffrey RadoChicago$208K
- K Ranga KrishnanChicago$92K
- Richard BaerChicago$44K
- Adam GoldenbergChicago$23K
- Olusola AjiloreChicago$21K
- Emil CoccaroChicago$20K
- Guarava AgarwalChicago$20K
- Jon GrantChicago$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.